esmo 2020 highlights on alpelisib plus fulvestrant for hr /her2– abc: the solar-1 study
Published 3 years ago • 1.5K plays • Length 2:26Download video MP4
Download video MP3
Similar videos
-
5:14
adding alpelisib for hr /her2- advanced breast cancer in solar-1: adverse event impacts
-
5:32
esmo 2020 expert video report on cdk4 6i in the adjuvant treatment of breast cancer
-
2:27
esmo 2020 highlights on neoadjuvant ici in early tnbc: the impassion031 study
-
3:11
esmo 2020 highlights on pembrolizumab in la-hnscc: the gortec 2015-01 “pembrorad” study
-
2:37
#esmo22 highlights on abemaciclib nsai in hr /her2- advanced breast cancer: the monarch 3 study
-
4:51
solar-1: alpelisib plus fulvestrant for advanced breast cancer
-
3:05
esmo 2020 highlights on sacituzumab govitecan in metastatic tnbc: the ascent study
-
3:21
esmo 2020 highlights on pembrolizumab as 1st line therapy for auc: the keynote-361 study
-
3:50
breast cancer at esmo 2020: impassion131, solar-1, pallas and more
-
2:39
esmo 2020 highlights on 1st line lorlatinib for alk nsclc: the crown study
-
3:04
esmo 2020 highlights on durability of clinical benefit and biomarkers with amg510 in nsclc
-
3:01
bylieve additional cohort: update on the trial of alpelisib in advanced breast cancer from esmo
-
2:35
esmo 2020 highlights on 1st line durvalumab and tremelimumab for mpdac: the pa.7 study
-
2:57
esmo 2020 highlights on lenvatinib plus pembrolizumab in advanced solid tumours: leap-005
-
0:55
esmo 2022 highlights
-
35:16
highlights from esmo 2020
-
5:12
monarch 2: abemaciclib added to fulvestrant shows os benefit in hr /her2- advanced breast cancer
-
3:27
alpelisib plus fulvestrant for hormone receptor positive metastatic breast cancer